How many clinical trials are tracked for Diffuse Large B-Cell Lymphoma?

179 trials are tracked, 8 with published results.

Diffuse Large B-Cell Lymphoma Research

Diffuse Large B-Cell Lymphoma: what the trials found

Several agents have demonstrated significant clinical activity in various treatment settings. Axicabtagene Ciloleucel showed superior event-free survival (8.3 vs. 2.0; p<0.0001), objective response rate (83% vs. 50%; p<0.0001), and overall survival (NA vs. 35.1%; p=0.027) compared to the control ¹². Rituximab-HDS demonstrated statistically significant improvements in event-free survival (65 vs. 62; p<0.05), disease-free survival (91 vs. 79; p<0.05), and overall survival (77 vs. 74; p<0.05) ¹⁵. Polatuzumab Vedotin showed significant improvements in progression-free survival (3.9; 2.7; 7.4; p<0.0001) and complete response rates (19.0% vs. 40.3%; p<0.0001) for Stage 2 patients, while also showing improved overall survival in Stage 2 (12.5 vs. 19.5; p=0.0017) ¹⁶.

Lenalidomide has been evaluated across multiple trials with varying results. In one study, it showed a high objective response rate of 90.9% in both arms (p=0.9964) and a complete response rate of 69.1% vs. 64.9% (p=0.2933) ⁸. Another trial reported progression-free survival at 18 weeks of 100%, 85.7%, 100%, and 90.0% across four groups ⁴. However, in a different study, the overall response rate for lenalidomide was not statistically significant (p=0.079) or (p=0.091) depending on the assessment criteria used ²¹.

Other established therapies include Cyclosporine ¹⁰, Enzastaurin Hydrochloride ¹³, and Pixantrone + Rituximab ¹⁴. While Everolimus showed a disease-free survival of 77.8% vs. 77.0% (p=0.276) ¹¹, Fludarabine Phosphate showed an overall survival of 65% vs. 54% (p=0.09) and a relapse/progression rate of 40% vs. 55% (p=0.06) ²². Rituximab was evaluated in multiple trials, showing no significant difference in progression-free survival compared to standard care ¹⁷ or in comparison to the RTXM83 variant ¹⁹.

For the clinician treating this condition

Axicabtagene Ciloleucel and Rituximab-HDS have demonstrated statistically significant improvements in survival and response metrics compared to their respective controls.
Polatuzumab Vedotin shows significant efficacy in Stage 2 patients, particularly regarding complete response rates and progression-free survival.
Evidence for lenalidomide is mixed; while some trials show high objective response rates, others do not reach statistical significance for overall response.
Rituximab remains a staple of treatment, but recent comparisons with specific variants (RTXM83) or other combinations have shown no statistically significant differences in progression-free survival.

AI synthesis of 14 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Diffuse Large B-Cell Lymphoma

Clinical Trials for Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma: what the trials found

Recent results — preliminary, needs further review

For the clinician treating this condition

Research across Non-Hodgkin's Lymphoma